Sales ban on eggs of women advances
By Capitol Media Services,
Capitol Media Services
| 02. 17. 2006
PHOENIX _ A House panel voted Thursday to criminalize the practice of buying and selling human eggs.
The 6-2 Judiciary Committee vote came after Rep. Bob Stump, R-Peoria, told colleagues that the methods used to harvest the eggs are potentially unsafe for women. Stump also said it is no more moral to sell human eggs than to sell body parts, a practice that already is illegal.
Part of his motive, he said, is to throw a roadblock into cloning research, a practice that often starts with human eggs.
House Bill 2142, which now goes to the full House, would subject violators, whether donors or companies that buy the eggs, to up to a year in jail.
Women could still donate eggs, whether for fertilization or research. But they could not get "money or other valuable consideration."
The call for human eggs, advertised in campus publications and some free weeklies, apparently can be lucrative: One company's classified ad says women can earn up to $24,000 for six separate egg donations.
"College women are targeted in particular," Stump said.
He said the...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...